AlphaCrest Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

AlphaCrest Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,805	Closed	-$968K	–	271
2022 Q3	$968K	Buy	+14,805	New	+$1.07M	0.06%	638
2022 Q1	–	Sell	-3,802	Closed	-$288K	–	1271
2021 Q4	$288K	Sell	3,802 -12,419	-77%	-$1.08M	0.01%	1262
2021 Q3	$1.82M	Buy	+16,221	New	+$2.04M	0.09%	353
2021 Q1	–	Sell	-1,400	Closed	-$214K	–	1203
2020 Q4	$214K	Buy	+1,400	New	+$165K	0.02%	1059

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

AlphaCrest Capital Management's CRSP Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 14,805 shares — an estimated $968K sold.

AlphaCrest Capital Management first reported a position in CRSP in Q4 2020 and held it in 4 quarters. The position peaked at $1.82M in Q3 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

AlphaCrest Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 14,805 CRISPR Therapeutics shares in Q4 2022, an estimated $968K.
AlphaCrest Capital Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 4 quarters.
AlphaCrest Capital Management's CRISPR Therapeutics position peaked at $1.82M in Q3 2021.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.